BPC-157
Body Protection Compound-157
Also known as: Pentadecapeptide, PL 14736, PL-10, Bepecin
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
A gastric pentadecapeptide with over 100 animal studies showing accelerated healing of tendons, muscles, gut lining, and other tissues. Uniquely stable in stomach acid, making it one of few peptides viable for oral use.
Quick Facts
Not FDA-approved for human use. Research compound only.
Overview
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It consists of 15 amino acids and is a partial sequence of body protection compound (BPC) that is naturally produced in the stomach.
Since its discovery, BPC-157 has been extensively studied in animal models for its remarkable tissue-healing properties. Research demonstrates effects on tendon, muscle, ligament, bone, and gut healing, along with protective effects on the liver, brain, and cardiovascular system.
Unlike most peptides, BPC-157 is stable in human gastric juice, which gives it the unique property of being potentially effective via oral administration — a significant advantage over peptides that require injection.
Mechanism of Action
BPC-157 operates through multiple interconnected pathways. Its primary mechanism involves upregulation of growth factor expression, particularly VEGF (vascular endothelial growth factor), which promotes angiogenesis — the formation of new blood vessels at injury sites.
It modulates the nitric oxide (NO) system, which plays a critical role in blood vessel function, inflammation, and tissue repair. BPC-157 appears to interact with the dopaminergic, serotonergic, and GABAergic systems, which may explain its observed effects on mood and neuroprotection.
At the cellular level, BPC-157 promotes fibroblast outgrowth and migration, accelerates collagen formation, and upregulates FAK-paxillin signaling — a pathway essential for cell migration to wound sites. It also counteracts the effects of several damaging agents including NSAIDs, alcohol, and various toxins on the gastrointestinal tract.
Research Summary
BPC-157 has been studied in over 100 preclinical studies, predominantly in rodent models. The research spans tendon healing (Achilles tendon transection models), muscle healing (crush injuries), ligament repair (medial collateral ligament), and bone fracture healing.
Gastrointestinal research shows significant protective and healing effects on inflammatory bowel disease models, gastric ulcers, and intestinal anastomosis healing. Studies demonstrate accelerated healing of esophageal, gastric, and duodenal lesions.
Neuroprotective research includes models of traumatic brain injury, peripheral nerve damage, and dopaminergic system protection. BPC-157 has shown protective effects against MPTP-induced neurotoxicity and cuprizone-induced demyelination.
A critical limitation: as of 2024, there are no published Phase II or Phase III human clinical trials. The evidence base, while extensive, remains preclinical. One small Phase II trial (PL 14736 for inflammatory bowel disease) has been referenced but results have not been fully published.
Key References
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P, et al. · Current Pharmaceutical Design (2011) · 10.2174/138161211796197115
Comprehensive review of BPC-157's gastrointestinal effects including ulcer healing, cytoprotection, and inflammatory bowel disease models.
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
Chang CH, et al. · Molecules (2014) · 10.3390/molecules191119066
Demonstrated BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, promoting tendon healing through enhanced GH signaling.
BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing
Seiwerth S, et al. · Current Pharmaceutical Design (2018) · 10.2174/1381612824666180712094658
Review of BPC-157's angiogenic properties and their role in tissue healing across multiple tissue types including tendon, ligament, and muscle.
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)
Sikiric P, et al. · Current Medicinal Chemistry (2012) · 10.2174/092986712800784066
Discussion of the IBD trial background for BPC-157, including the development pathway for PL 14736 and evidence supporting its anti-inflammatory effects.
Protocols
Systemic healing (research-based)
Inject near the site of injury when possible. Lower dose (250 mcg) for general recovery, higher dose for acute injuries.
Oral (gut-focused)
BPC-157 is stable in gastric juice, making oral administration viable. Primarily used for GI-related applications.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Injection site redness or irritation Typically mild and resolves within hours. |
| uncommon | Nausea More common with oral administration. Usually mild. |
| uncommon | Dizziness Reported anecdotally. May be related to blood pressure changes. |
| rare | Headache |
Contraindications
- —Active cancer or history of cancer (theoretical concern due to angiogenic properties)
- —Pregnancy or breastfeeding
- —Concurrent use of medications that affect coagulation (insufficient interaction data)
Interactions
- —May interact with blood pressure medications via NO system modulation
- —Theoretical interaction with anticoagulants due to effects on blood vessel formation
- —May modulate the effects of dopaminergic medications
Reconstitution & Storage
Related Peptides
Frequently used alongside TB-500 for enhanced healing. The combination targets complementary pathways — BPC-157 promotes angiogenesis while TB-500 promotes actin regulation and cell migration.